Some new mechanisms underlying the actions of(–)-deprenyl: Possible relevance to neurodegeneration

Progress in Brain Research

Volumn 106, Issue C, 1995, Pages 99-112

  Li, Xin Min ^a   Juorio, Augusto V ^a   Boulton, Alan A ^a  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATIC LEVO AMINO ACID DECARBOXYLASE; CLORGYLINE; INTERLEUKIN 1BETA; LAZABEMIDE; MOFEGILINE; MONOAMINE OXIDASE INHIBITOR; PARGYLINE; PROSTAGLANDIN; SELEGILINE;

ANIMAL CELL; CELL CULTURE; CONTROLLED STUDY; GENE EXPRESSION; GLIOMA; IMMUNOBLOTTING; NERVE DEGENERATION; NONHUMAN; PHEOCHROMOCYTOMA; PRIORITY JOURNAL; REVIEW;

EID: 0029619614     PISSN: 00796123     EISSN: 18757855     Source Type: Book Series    
DOI: 10.1016/S0079-6123(08)61207-8     Document Type: Article

References (129)

1. Albert, V.R., Allen, J.M., Joh, T., A single gene codes for aromatic L-amino acid decarboxylase in both neuronal and non-neuronal tissues. J. Biol. Chem. 262 (1987), 9404–9411.
2. Altar, C.A., Boylan, C.B., Jackson, C., Hershenson, S., Miller, J., Wiegand, S.J., Lindsy, M., Hyman, C., Brainderived neurotrophic factor augments rotational behavior and nigrostriatal dopamine turnover in vivo. Proc. Natl. Acad. Sci. USA 89 (1992), 11347–11351.
3. Amenta, F., Bograni, S., Cadel, S., Ferrante, F., Valsecchi, B., Vega, J., Microanatomical changes in the frontal cortex of aged rats: effect of l-deprenyl treatment. Brain Res. Bull. 34 (1994), 125–131.
4. Ansari, K.S., Tatton, W.G., Yu, P.H., Kruck, T.P.A., Death of axotomized immature rat facial motoneurons: stereospecific rescue by R(—)-deprenyl independently of MAO inhibition. Neuroscience 13 (1993), 4042–4053.
5. Arakawa, Y., Sendtner, M., Thoenen, H., Survival effect of ciliary neurotrophic factor (CNTF) on chick embryonic motoneurons in culture: comparison with other neurotrophic factors and cytokines. J. Neurosci. 10 (1990), 3507–3515.
6. Aschner, M., Kimelberg, H.K., The use of astrocytes in culture as model systems for evaluating neurotoxic-induced-injury. Neurotoxicology 12 (1991), 505–517.
7. Assouline, J.G., Bosch, P., Lim, R., Kim, I.S., Jensen, R., Pantazis, N.J., Rat astrocytes and Schwann cells in cultures synthesize nerve growth factor-like neurite-promoting factors. Dev. Brain Res. 31 (1987), 103–118.
8. Barber, A.J., Paterson, I.A., Gelowitz, D.L., Voll, C.L., Deprenyl protects rat hippocampal pyramidal cells from ischaemic insult. Soc. Neurosci. Abstr. 19 (1993), 67–76.
9. Beall, C.J., Hirsh, J., Regulation of the Drosophila dopa decarboxylase gene in neuronal and glial cells. Gene Deu. 1 (1987), 510–520.
10. Bertocci, B., Gill, G., DaPrada, M., Prevention of the DSP4-induced noradrenergic neurotoxicity by irreversible, not by reversible MAO-B inhibitors. Pharmacol. Res. Commun. 20:Suppl 5 (1988), 131–132.
11. Biagini, G., Zoli Fuxe, M., Agnati, K.L.F., L-Deprenyl increases GFAP immunoreactivity selectively in activated astrocytes in rat brain. Neuroreport 4 (1993), 955–958.
12. Birkmayer, W., Knoll, J., Riederer, P., Deprenyl leads to prolongation of l-Dopa efficacy in Parkinson's disease. Beckmann, H., Riederer, P., (eds.) Monoamine Oxidase and its Selective Inhibitors, 1983, Karger, Basel, 170–176.
13. Birkmayer, W., Riederer, P., Youdim, M.B., Linauer, W., The potentiation of the anti-akinetic effect of l-dopa treatment by an inhibitor of MAO-B, l-deprenyl. J. Neural Transm. 36 (1975), 303–336.
14. Birkmayer, W, Riederer, P, Ambrozi, L., Youdim, M.B., Implications of combined treatment with ‘Madopar’ and L-deprenyl in Parkinson's disease, a long term study. Lancet 1 (1977), 439–443.
15. Boulton, A.A., Cerebral aryl alkyl aminergic mechanisms. Usdin, E., Sandler, M., (eds.) Trace Amines and the Brain. Vol. I: Psychopharmacology Series, 1976, M. Dekker, New York, 22–39.
16. Boulton, A.A., Juorio, A.V., Brain trace amines. Lajtha, A., (eds.) Handbook of Neurochemistry, I, 1982, Plenum Press, New York, 189–222.
17. Bowsher, R.R., Henry, D.P., Decarboxylation of p-tyrosine: a potential source of p-tyramine in mammalian tissues. J. Neurochem. 40 (1983), 992–1002.
18. Brodie, B.B., Kuntzman, R., Hirch, C.W., Costa, E., Effects of decarboxylase inhibition on the biosynthesis of brain monoamines. Life Sci. 1 (1962), 81–84.
19. O'Buckland, P.R., Donovan, M.C., McGuffin, P., Changes in dopa decarboxylase mRNA but not tyrosine hydroxylase mRNA levels in rat brain following antipsychotic treatment. Psychopharmacology 108 (1992), 98–102.
20. Buu, N.T., Angers, M., Effects of different monoamine oxidase inhibitors on the metabolism of L-Dopa in the rat brain. Biochem. Pharmacol 36 (1987), 1731–1735.
21. Campbell, I.C., Murphy, D.L., Walker, M.N., Lovenberg, W., Monoamine oxidase inhibitors (MAOI) increase rat brain aromatic amino acid decarboxylase activity. Br. J. Clin. Pharmacol 9 (1980), 431–432.
22. Carman-Krzan, M., Vige, X., Wise, B.C., Regulation by interleukin-1 of nerve growth factor secretion and nerve growth factor mRNA expression in rat primary astroglial cultures. J. Neurochem. 56 (1991), 636–643.
23. Carrillo, M.C., Kanai, S., Nokubo, M., Kitani, K., Deprenyl induces activities of both superoxide dismutase and catalase but not of glutathione peroxidase in the striatum of young male rats. Life Sci. 48 (1991), 517–521.
24. Chan-Palay, V., Asan, E., Alteration in catecholamine neurons of the locus coeruleus in senile dementia of the Alzheimer type and in Parkinson's disease with and without dementia and depression. J. Comp. Neural. 287 (1989), 373–392.
25. Christenson, J.W., Dairman, W., Udenfriend, S., On the identity of DOPA decarboxylase and 5-hydroxytryptophan decarboxylase. Proc. Natl. Acad. Sci. USA 69 (1972), 343–347.
26. Coge, F., Krieger-Poullet, M., Gros, F., Thibault, J., Comparative and quantitative study of L-DOPA decarboxylase mRNA in rat neuronal and non-neuronal tissues. Biochem. Biophys. Res. Commun. 170 (1990), 1006–1012.
27. Cooper, J., Drug treatment of Alzheimer's disease. Arch. Intern. Med. 151 (1991), 245–249.
28. Damier, P., Hirsch, E.C., Zhang, P., Agid, Y., Javoy-Agid, F., Glutathione peroxidase, glial cells and Parkinson's disease. Neuroscience 52 (1993), 1–6.
29. David, J.C., Coulon, J.F., Cavoy, A., Delacour, J., Effects of aging on p- and m-octopamine, catecholamines, and their metabolizing enzymes in the rat. J. Neurochem. 53 (1989), 149–154.
30. Davis, K.L., Haroutunian, V., Strategies for the treatment of Alzheimer's disease. Neurology 43:suppl. 4 (1993), 52–55.
31. Easter, W., Purves, D., Rakee, P., Spitzer, N.C., The changing view of neural specificity. Science 230 (1985), 507–511.
32. Eaton, M.J., Gudehithlu, K.P., Quach, T., Silvia, C.P., Hadjiconstantinou, M., Neff, N.H., Distribution of aromatic l-amino acid decarboxylase mRNA in mouse brain by in situ hybridization histology. J. Comp. Neurol. 337 (1993), 640–654.
33. Ekblom, J., Jossan, S.S., Ebendal, T., Soderstrom, S., Oreland, L., Aquilonius, S.-M., mRNA expression of neurotrophins and members of the trk family in the rat brain after treatment with l-deprenyl. Acta Neural. Scand. 89 (1994), 147–148.
34. Fainberg, A.P., Vogelstein, B., A technique for radiolabelling DNA restriction endonuclease fragments to high specific activity. Anal. Biochem. 132 (1983), 6–13.
35. Feinstein, D.L., Weinmaster, G.A., Milner, R.J., Isolation of cDNA clones encoding rat glial fibrillary acidic protein: expression in astrocytes and in Schwann cells. J. Neurosci. Res. 32 (1992), 1–14.
36. Finnegan, K.T., Skratt, J.J., Irwin, I., DeLanney, L.E., Langston, J.W., Protection against DSP-4-induced neurotoxicity by deprenyl is not related to its inhibition of MAO B. Eur. J. Pharmacol 184 (1990), 119–126.
37. Francis, J., Thompson, R., Bernal, S.D., Luk, G.D., Baylin, S.B., Effects of dibutyryl cyclic adenosine 3′:5′-monophosphate on the growth cultured human small-cell lung carcinoma and the specific cellular activity of L-Dopa decarboxylase. Cancer Res. 43 (1983), 639–645.
38. Friden, P.M., Walus, L.R., Watson, P., Doctrw, S.R., Kozarich, J.W., Backman, C., Bergman, H., Hoffer, B., Bloom, F., Granholm, A.-C., Blood-brain barrier penetration and in vivo activity of an NGF conjugate. Science 259 (1993), 373–377.
39. Furukawa, S., Furukawa, Y., Nerve growth factor synthesis and its regulatory mechanisms: an approach to therapeutic induction of nerve growth factor synthesis. Cerebrouasc. Brain Metab. Rev. 2 (1990), 328–344.
40. Furukawa, Y., Tomioka, N., Sato, W., Satoyoshi, E., Hayashi, K., Furukawa, S., Catecholamines increase nerve growth factor mRNA content in both mouse astroglial cells and fibroblast cells. FEBS Lett. 247 (1992), 463–467.
41. Fusco, M., Polato, P., Vantini, G., Cavicchioli, L., Bentivoglio, M., Leon, A., Nerve growth factor differentially modulates the expression of its receptor within the CNS. J. Comp. Neural. 312 (1991), 477–491.
42. Gelowitz, D.L., Paterson, I.A., L-deprenyl reduces kainic acid-induced neuronal death in the hippocampus. Soc. Neurosci. Abstr. 20 (1994), 11–32.
43. Gibson, C.J., Inhibition of MAO B, but not MAO A, blocks DSP-4 toxicity on central NE neurons. Eur. J. Pharmacol 141 (1987), 135–138.
44. Gjedde, A., Leger, G.C., Cumming, P., Yasuhara, Y., Evans, A.C., Guttman, M., Kuwabara, H., Striatal l-dopa decarboxylase activity in Parkinson's disease in vivo: implications for the regulation of dopamine synthesis. J. Neurochem. 61 (1993), 1538–1541.
45. Gottlieb, G.L., Kumar, A., Conventional pharmacologic treatment for patients with Alzheimer's disease. Neurology 43:suppl 4 (1933), 56–63.
46. Goad, D.L., Davis, C.M., Liem, P., Fuselier, C.C., McCormack, J.R., Olsen, K.M., The use of selegiline in Alzheimer's patients with behavior problems. J. Clin. Psychiat. 52 (1991), 342–345.
47. Hadjiconstantinou, M., Rossetti, Z., Silvia, C, Krajnc, D., Neff, N.H., Aromatic l-amino acid decarboxylase activity of the rat retina is modulated in vivo by environmental light. J. Neurochem. 51 (1988), 1560–1564.
48. Heikkila, R.E., Manzino, L., Cabbat, F.S., Duvoisin, R.C., Protection against the dopaminergic neurotoxicity of l-methyl-4-phenyl-1,2,3,6-tetraydropyridine by monoamine oxidase inhibitors. Nature 311 (1984), 467–469.
49. Hornykiewicz, O., The mechanisms of action of L-dopa in Parkinson's disease. Life Sci. 15 (1974), 1249–1259.
50. Hörtnagl, H., Berger, M.L., Havelec, L., Hornykiewicz, O., Role of glucocorticoids in the cholinergic degeneration in rat hippocampus induced by ethylcholine aziridinium (AF64A). J. Neurosci. 13 (1993), 2939–2945.
51. Ichinose, H., Kurosawa, Y., Titani, K., Fujita, K., Nagatsu, T., Isolation and characterization of a cDNA clone encoding human aromatic L-amino acid decarboxylase. Biochem. Biophys. Res. Commun. 164 (1989), 1024–1030.
52. Jaeger, C.B., Teitelman, G., Joh, T.H., Albert, V.R., Park, D.H., Reis, D.J., Some neurons of the rat central nervous system contain aromatic 1-amino acid decarboxylase but not monoamine. Science 219 (1983), 1233–1235.
53. Johnston, J.P., Some observations upon a new inhibitor of monoamine oxidase in brain tissue. Biochem. Pharmacol 17 (1968), 1285–1297.
54. Juorio, A.V., Boulton, A.A., The effect of some precursor amino acids and enzyme inhibitors on the mouse striatal concentration of tyramines and homovanillic acid. J. Neurochem. 39 (1982), 859–863.
55. Juorio, A.V., Paterson, I.A., Tryptamine may couple dopaminergic and serotonergic transmission in the brain. Gen. Pharmacol 21 (1990), 759–762.
56. Juorio, A.V., Li, X.-M., Walz, W., Paterson, I.A., Decarboxylation of L-Dopa by cultured mouse astrocytes. Brain Res 626 (1993), 306–309.
57. Juorio, A.V., Li, X.-M., Paterson, I.A., Boulton, A.A., Effects of monoamine oxidase B inhibitors on dopaminergic function: role of 2-phenylethylamine and aromatic L-amino acid decarboxylase. Olanow, C.W., Lieberman, A., (eds.) MAO Inhibitors in Neurological Disease, 1993, Budapest, 181–200.
58. Kang, U.J., Joh, T.H., Deduced amino acid sequence of bovine aromatic L-amino acid decarboxylase: homology to other decarboxylase. Mol. Brain Res. 8 (1990), 83–87.
59. Karoum, F., Chuang, L.W., Eisler, T., Calne, D.B., Liebowitz, M.R., Quitkin, F.M., Klein, D.F., Wyatt, R.J., Metabolism of (—)deprenyl to amphetamine and methamphetamine may be responsible for deprenyl's therapeutic benefit: A biochemical assessment. Neurology 32 (1982), 503–509.
60. Kitani, K., Kanai, S., Sato, Y., Ohta, M., Ivy, G.O., Carrillo, M-C., Chronic treatment of (-)deprenyl prolongs the life span of male fischer 344 rats: further evidence. Life Sci. 52 (1992), 281–288.
61. Knoll, J., Magyar, K., Some puzzling pharmacological effects of monoamine oxidase inhibitors. Adv. Biochem. PsychoPharmacol 5 (1972), 393–408.
62. Knoll, J., The possible mechanisms of action of (-)deprenyl in Parkinson's disease. J. Neural. Transm. 43 (1978), 117–198.
63. Knoll, J., Dallo, J., Yen, T.T., Striatal dopamine, sexual activity and lifespan, longevity of rats treated with (-)deprenyl. Life Scl. 45 (1989), 525–531.
64. Komori, D., Fujii, T., Karasawa, N., Yamada, K., Nagatsu, I., Some neurons of the nouse cortex and caudoputamen contain aromatic L-amino acid decarboxylase but not monoamines. Acta Histochem. Cytochem. 24 (1991), 571–577.
65. Konradi, C., Kornhuber, J., Froelich, L., Fritze, J., Heinsen, H., Beckmann, H., Schulz, E., Riederer, P., Demonstration of MAO A and B in the hyman brainstem by a histochemical technique. Neuroscience 33 (1989), 383–400.
66. Kwok, R.P.S., Juorio, A.V., The concentration of striatal tyramine and dopamine metabolism in diabetic rats and effect of insulin administration. Neuroendocrinology 43 (1986), 590–596.
67. Langelier, P., Roberge, A.G., Boucher, R., Poirier, L., Effects of chronically administered L-DOPA in normal and lesioned cats. J. Pharmacol. Exp. Ther. 187 (1973), 15–22.
68. Leibrock, J., Lottspeich, F., Hohn, A., Hofer, M., Hengerer, B., Masiakowski, P., Thoenen, H., Barde, Y.A., Molecular cloning and expression of brain-derived neurotrophic factor. Nature 351 (1989), 149–152.
69. Levi-Montalcini, R., The nerve growth factors 35 years later. Science 237 (1987), 1154–1162.
70. Li, X-M., Juorio, A.V., Paterson, I.A., Walz, W., Zhu, M.Y., Boulton, A.A., Gene expression of aromatic L-amino acid decarboxylase in rat cultured glial cells. J. Neurochem. 59 (1992), 1172–1175.
71. Li, X-M., Juorio, A.V., Paterson, I.A., Zhu, M.Y., Boulton, A.A., Specific irreversible MAO B inhibitors stimulate gene expression of aromatic l-amino acid decarboxylase in PC12 cells. J. Neurochem. 59 (1992), 2324–2327.
72. Li, X.-M., Juorio, A.V., Boulton, A.A., Gene regulation of aromatic l-amino acid decarboxylase (AADC) by NSD-1015 in rat PC12 pheochromocytoma cells. Neurochem. Res. 18 (1993), 915–919.
73. Li, X.-M., Qi, J., Juorio, A.V., Boulton, A.A., Reduction in GFAP mRNA abundance induced by (-)-Deprenyl and other MAO B inhibitors in C6 Glioma Cells. J. Neurochem. 61 (1993), 1573–1576.
74. Li, X.-M., Juorio, A.V., Boulton, A.A., Induction of aromatic l-amino acid decarboxylase mRNA by interleukin-1β and prostaglandin E2. Neurochem. Res 19 (1993), 593–597.
75. Lloyd, K.G., Hornykiewicz, O., Parkinson's disease, activity of L-dopa decarboxylase in discrete brain regions. Science 170 (1970), 1212–1213.
76. Lovenberg, W., Weissbach, W., Udenfriend, S., Aromatic L-amino acid decarboxylase. J. Biol. Chem. 237 (1962), 89–93.
77. Maniatis, T., Fritsch, E.F., Sambrook, J., Molecular Cloning, a Laboratory Manual, 1982, Cold Spring Harbor, New York.
78. Mangoni, A., Grassi, M.P., Frattola, L., Piolti, R., Bassi, S., Motta, A., Marcone, A., Smirne, S., Effects of a MAO-B inhibitor in the treatment of Alzheimer disease. Eur. Neural. 31 (1991), 100–107.
79. Matsui, Y., Kumagae, K., Monoamine oxidase inhibitors prevent striatal neuronal necrosis induced by transient forebrain ischemia. Neurosci. Lett. 126 (1991), 175–178.
80. Milgram, N.W., Racine, R.J., Nellis, P., Mendonca, A., Ivy, G.O., Maintenance on l-deprenyl prolongs life in aged male rats. Life Sci. 47 (1990), 415–420.
81. Nagatsu, Y., Yamamoto, T., Kato, T., A new and highly sensitive voltammetric assay for AADC activity by high-performance liquid chromatography. Anal. Biochem. 100 (1979), 160–165.
82. Neff, N.H., Yang, H.-Y.T., Another look at the monoamine oxidases and the monoamine oxidase inhibitor drugs. Life Sci. 14 (1974), 2061–2074.
83. Ng, L.K.Y., Chase, T.N., Colburn, R.W., Kopin, I.J., L-dopa in parkinsonism: a possible mechanism of action. Neurology 22 (1972), 688–696.
84. Nomoto, M., Fukuda, T., A selective MAO B inhibitor Ro19-6327 potentiates the effects of levodopa on parkinsonism induced by MPTP in the common marmoset. Neuropharmacology 32 (1993), 473–477.
85. Norton, W.T., Aquino, D.A., Hozumi, I., Chiu, F.C., Brosnan, C.F., Quantitative aspects of reactive gliosis: a review. Neurochem. Res. 17 (1992), 877–885.
86. Olson, L., Henschen, A., Eriksdotter-NilssonStromberg, M., Wetmore, E.C., Ernfors, P., Friedman, W., Persson, H., Ebendal, T., The expanding role of nerve growth factor in the central nervous system. Sara, V., (eds.) Growth Factors: From Genes to Clinical Application, 1990, Raven Press, New York, 167–177.
87. Palmer, A.M., DeKosly, S.T., Monoamine neurons in aging and Alzheimer's disease. J. Neural. Transm. 91 (1993), 135–139.
88. Paterson, I.A., Juorio, A.V., Berry, M.D., Zhu, M.Y., Inhibition of monoamine oxidase-B by (-)-deprenyl potentiates neuronal responses to dopamine agonists but not inhibit dopamine catabolism in the rat striatum. J. Pharmacol. Exp. Ther. 258 (1991), 1019–1026.
89. Paterson, I.A., Juorio, A.V., Boulton, A.A., 2-Phenylethylamine: a modulator of catecholamine transmission in the central nervous system. J. Neurochem. 55 (1990), 1827–1837.
90. Philips, S.R., Boulton, A.A., The effect of monoamine oxidases on some arylalkylamines in rat striatum. J. Neurochem. 33 (1979), 159–167.
91. Phillips, H.S., Hains, J.M., Armanini, M., Laramee, G.R., Johnson, S.A., Winslow, J.W., BDNF mRNA is decreased in the hippocampus of individuals with Alzheimer's disease. Neuron 7 (1991), 695–702.
92. Reisberg, B., An overview of current concepts of Alzheimer's disease, senile dementia, and age-associated cognitive decline. Reisberg, B., (eds.) Alzheimer's Disease, The Standard Reference, 1983, Free Press, New York, 6–9.
93. Ricci, A., Mancini, M., Strocchi, P., Bongrani, S., Bronzetti, E., Deficits in cholinergic neurotransmission markers induced by ethylcholine mustard aziridinium (AF64A) in the rat hippocampus: sensitivity to treatment with the monoamine oxidase-B inhibitor l-deprenyl. Drugs Exp. Clin. Res. 18 (1992), 163–171.
94. Riederer, P, Youdim, M.B., Rausch, W.D., On the mode of action of L-deprenyl in the human central nervous system. J. Neural Transm. 43 (1978), 217–226.
95. Rinne, U.K., Deprenyl (selegiline) in the treatment of Parkinson's disease. Acta Neural. Scand. 95:suppl. (1983), 107–111.
96. Robins, E., Robins, J.M., Croninger, A.B., Moses, S.G., Spencer, J., Hudgens, R.W., The low level of 5-HTP decarboxylase in human brain. Biochem. Med. 1 (1967), 240–251.
97. Robinson, D.S., Campbell, I.C., Walker, M., Statham, N., Lovenberg, W., Murphy, D.L., Effect of chronic monoamine oxidase inhibitor treatment on biogenic amine metabolism in rat brain. Neumpharmacology 18 (1979), 771–776.
98. Rossetti, Z.L., Silvia, C.P., Krajnc, D., Neff, N.H., Hadjiconstantinou, M., Aromatic l-amino acid decarboxylase is modulated by D1 dopamine receptors in rat retina. J. Neurochem. 54 (1990), 787–791.
99. Salo, P.T., Tatton, W.G., Deprenyl reduces the death of motoneurons caused by axotom. J. Neurosci. Res. 31 (1992), 394–400.
100. Schnaitman, C., Erwin, V.G., Greenawalt, J.W., The submitocondrial localization of monoamine oxidase: an enzymatic marker for the outer membrane of rat liver mitocondria. J. Cell Biol. 32 (1967), 719–735.
101. Sendtner, M., Schmalbruch, H., Stockli, K.A., Carroll, P., Kreutzberg, G.W., Thoenen, H., Ciliary neurotrophic factor prevents degeneration of moter neurons in mouse mutant progressive motor neuronopathy. Nature 358 (1992), 502–504.
102. Shinoda, I., Furukawa, Y., Furukawa, S., Stimulation of nerve growth factor synthesis secretion by propentofylline in cultured mouse astroglial cells. Biochem. Pharmacol 39 (1990), 1813–1816.
103. Skibo G, I. Ahmed, P. Yu, A.A. Boulton, S. Fedoroff, 1992 l-Deprenyl, a monoamine oxidase-B inhibitor acts on the astroglia cell cycle at the G1/G0 boundary. Abstr. Annu. Meet. Am. Soc. Cell Biol.
104. Sumi-Ichinose, C., Ichinose, H., Takahashi, E., Hori, T., Nagatsu, T., Molecular cloning of genomic DNA and chromosomal assignment of the gene for human aromatic L-amino acid decarboxylase, the enzyme for catecholamine and serotonin synthesis. Biochemistry 31 (1992), 2229–2238.
105. Sunderland, T., Tariot, P.N., Cohen, R.M., Newhouse, P.A., Mellow, A.M., Mueller, E.A., Murphy, D.L., Dose-dependent effects of deprenyl on CSF monoamine metabolites in patients with Alzheimer's disease. Psychopharmacology 91 (1987), 293–296.
106. Takeuchi, R., Murase, K., Furukawa, Y., Furukawa, S., Hayashi, K., Stimulation of nerve growth factor synthesis/secretion by 1,4-benzoquinone and its derivatives in cultured mouse astroglial cells. FEBS. Lett. 12 (1990), 63–66.
107. Tanaka, T., Horio, Y., Taketoshi, M., Imamura, I., Ando-Yamamoto, M., Kangawa, K., Matsuo, H., Kuroda, M., Waka, H., Molecular cloning and sequencing of a cDNA of rat dopa decarboxylase, partial amino acid homologies with other enzymes synthesizing catecholamines. Proc. Natl. Acad. Sci. USA 86 (1989), 8142–8146.
108. Tardy, M., Fages, C., Riol, H., LePrince, G., Rataboul, P., Charriere-Bertrand, C., Nunez, J., Developmental expression of the glial fibrillary acidic protein mRNA in the central nervous system and in cultured astrocytes. J. Neurochem. 52 (1989), 162–167.
109. Tariot, P.N., Sunderland, T., Weingartner, H., Murphy, D.L., Welkowitz, J.A., Thompson, K., Cohen, R.M., Cognitive effects of l-deprenyl in Alzheimer's disease. Psychopharmacology 91 (1987), 489–495.
110. Tatton, W.G., Greenwood, C.E., Rescue of dying neurons, a new action for deprenyl in MPTP parkinsonism. J. Neurosci. Res. 30 (1991), 666–672.
111. Tatton, W.G., Ju, W.Y.L., Holland, D.P., Tai, C., Kwan, M., (-)-Deprenyl Reduceds PC12 cell apoptosis by inducing new protein synthesis. J Neurochem 63 (1994), 1572–1575.
112. Tetrud, J.W., Langston, J.W., The effect of deprenyl (selegiline) on the natural history of Parkinson's disease. Science 245 (1989), 519–522.
113. Tetrud, J.W., Langston, J.W., Effect of deprenyl on the progression of disability in early Parkinson's disease. N. Engl. J. Med. 321 (1989), 1364–1371 The Parkinson Study Group.
114. Tetrud, J.W., Langston, J.W., Effect of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N. Engl. J. Med. 328 (1993), 176–183 The Parkinson Study Group.
115. Thoenen, H., Barde, Y.-A., Physiology of nerve growth factor. Physiol. Rev. 60 (1980), 1285–1335.
116. Tipton, K., Biochemical aspects of monoamine oxidase. Br. Med. Bull. 29 (1973), 116–119.
117. TosoDe, R., Bernardi, M., Brooker, G., Costa Mocchetti, E., Beta adrenergic and prostaglandin receptor activation increases nerve growth factor mRNA content in C6-2B rat astrocytoma cells. J. Pharmacol. Exp. Ther. 246 (1988), 1190–1193.
118. Vrana, S.L., Azzaro, A.J., Vrana, R.E., Chronic selegiline trasiently decreases tyrosine hydroxylase activity and mRNA in the rat nigrostriatal pathway. Mol. Pharmacol 41 (1992), 839–844.
119. Varon, S., Bunge, R.P., Trophic mechanisms in the peripheral nervous system. Annu. Rev. Neurosci. 1 (1978), 327–361.
120. Whittemore, S.W., Seiger, A., The expression, localization and functional significance of b-nerve growth factor in the central nervous system. Brain Res. Rev. 12 (1987), 439–464.
121. Youdim, B.M.H., The active centres of monoamine oxidase types ‘A’ and ‘B’: binding with (14C)-clorgyline and (14C)-deprenyl. J. Neural Transm. 43 (1978), 199–208.
122. Youdim, B.M.H., Heldman, E., Pollard, H.B., Fleming, P., McHugh, E., Contrasting monoamine oxidase activity and tyramine induced catecholamine release in PC 12 and chromaffin cells. Neuroscience 19 (1986), 1311–1318.
123. Young, E.A., Neff, N.H., Hadjiconstantinou, M., Evidence for cyclic AMP-mediated increase of aromatic L-amino acid activity in the striatum and midbrain. J. Neurochem. 60 (1993), 2331–2333.
124. Yu, P.H., Davis, B.A., Boulton, A.A., Aliphatic propargylamines: potent, selective irreversible monoamine oxidase B inhibitors. J. Med. Chem. 35 (1992), 3705–3713.
125. YuDavis, P.H., Fang, B.A.J., Boulton, A.A., Neuroprotective effects of some MAOIs against DSP-4 induced NA depletion iin the mouse hioppocampus. J. Neurochem. 63 (1994), 1820–1828.
126. YuDavis, P.H., Durden, B.A.D.A., Barber, A., Terleckyj, I., Nicklas, W.G., Boulton, A.A., Neurochemical and neuroprotective effects of some aliphatic propargylamines: new selective non-amphetamine-like MAO B inhibitors. J. Neurochem. 62 (1994), 697–704.
127. Zhu, M.Y., Juorio, A.V., Paterson, I.A., Boulton, A.A., Regulation of aromatic l-amino acid decarboxylase by dopamine receptors in the rat brain. J. Neurochem. 58 (1992), 636–641.
128. Zhu, M.-Y., Juorio, A.V., Paterson, I.A., Boulton, A.A., Regulation of aromatic L-amino acid decarboxylase in rat striatal synaptosomes: Effects of dopamine receptor agonists and antagonists. Br. J. Pharmacol 112 (1994), 23–30.
129. FöZsilla, G., Uldi, P., SzeHeld, G., Akely, A.M., Knoll, J., The effect of repeated doses of repeated doses of (-) deprenyl on the dynamics of monoaminergic transmission. Comparison with clorgyline. Pol. J. Pharmacol. Pharm. 38 (1986), 57–67.